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We traced the Chlamydia trachomatis L2b variant in
Amsterdam and San Francisco. All recent lymphogranulo-
ma venereum cases in Amsterdam were caused by the L2b
variant. This variant was also present in the 1980s in San
Francisco. Thus, the current “outbreak” is most likely a
slowly evolving epidemic.
S
ince the end of 2003, an ongoing lymphogranuloma
venereum (LGV) proctitis outbreak has been reported
in industrialized countries, first in the Netherlands, fol-
lowed by neighboring European countries and the United
Kingdom, and now in the United States and Canada (1–4).
We recently identified a new LGV variant designated L2b
(GenBank accession no. AY586530) in all our cases in
2002 and 2003 that suggests this LGV outbreak was new
(5). Until now, only men who have sex with men (MSM)
are affected, and most are HIV co-infected. Although these
infections, which can be caused by LGV serovars L1, L2,
L2a, and L3, are often characterized by severe inflamma-
tory symptoms, delayed or incorrect diagnosis has
increased both the risk for transmission and the develop-
ment of severe sequelae. Successful treatment of LGV
proctitis requires a 3-week course of doxycycline followed
by a test of cure, whereas in the case of Chlamydia tra-
chomatis proctitis caused by serovars D–K, a 1-week
course will suffice.
In a recent article on this LGV outbreak (3), 2 issues
were stressed: 1) the lack of an easy diagnostic tool and 2)
whether lymphogranuloma venereum is a new problem or
whether it has been present but undiagnosed. Indeed,
among the obstacles to the correct diagnosis of LGV is the
lack of a commercially available assay to specifically dis-
tinguish between C. trachomatis infections caused by
LGV serovars and infections caused by less invasive C.
trachomatis serovars. A definitive diagnosis of LGV is
currently made with nucleic acid sequence-based tests, like
polymerase chain reaction (PCR)–based restriction frag-
ment length polymorphism (RFLP) analysis, which are
only available in a few specialized laboratories. We recent-
ly developed a real-time PCR (TaqMan and RotorGene)
that can specifically distinguish LGV infections from
infections with other C. trachomatis serovars, which facil-
itates diagnosis (6).
We used this new diagnostic tool to determine whether
the LGV outbreak and its cause are a new phenomenon or
whether LGV C. trachomatis serovars have been present
much longer but have gone undiagnosed. First, we deter-
mined if the newly identified Amsterdam L2b variant was
already present in the MSM population before 2002 by
using stored samples collected from MSM with and with-
out proctitis who sought treatment at the sexually transmit-
ted infections (STI) outpatient clinic in Amsterdam.
Second, we performed the same analysis on archived spec-
imens from MSM in San Francisco, California, collected
20–25 years ago.
The Study
From MSM who attended the Amsterdam Municipal
Health Service STI Outpatient Clinic in 2000 and 2001,
randomly selected stored specimens of C. trachomatis
DNA–positive (as assessed by ligase chain reaction,
Abbott Laboratories, Chicago, IL, USA) rectal samples
were tested for the C. trachomatis variant by real-time
PCR (6). From 2002 to 2005, MSM with symptomatic
proctitis (i.e., purulent discharge, rectal ulceration, bleed-
ing, or edematous mucosa) and MSM without symptoms
were included.
From the San Francisco region, 51 LGV–positive iso-
lates from symptomatic MSM were analyzed (7). The iso-
lates were collected in medical clinics (e.g., ambulatory
care, emergency room, screening, acute care) from 1979 to
1985 (Table). LGV was assessed at the time of collection,
according to phenotypic properties observed during cell
culture. Although the growth characteristics of LGV
serovars can be distinguished from serovars D–K, cell cul-
ture for C. trachomatis is no longer available in most clin-
ical settings.
C. trachomatis serovar typing was performed as
described previously (5). Briefly, amplification of the
ompA gene (1.1 kb) was performed in a nested PCR for-
mat. Serovars and variants were initially identified by their
RFLP patterns after polyacrylamide gel electrophoresis.
The ompA nucleotide sequences were subsequently ana-
lyzed by automated DNA sequencing on an ABI 310
sequencer (PE Biosystems, Foster City, CA, USA). The
sequences obtained from C. trachomatis–infected MSM in
2000 and 2001 in Amsterdam and from MSM in San
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Table presents the results of this analysis.
In the Amsterdam C. trachomatis DNA–positive rectal
samples, LGV strains were detected by real-time PCR in 2
of 67 samples in 2000 and in 4 of 28 samples in 2001.
Sequencing showed that in all 6 LGV strain–positive sam-
ples, the L2b variant was present. Also in 2002 and 2003,
109 L2b-positive samples of 403 C. trachomatis
DNA–positive rectal samples were identified, of which 45
were strain L2b, and these have been described in a previ-
ous publication (5). All 51 San Francisco specimens (from
51 patients) were positive for LGV variants by real-time
PCR. By sequencing variable segment 2 of the ompA gene
(VS-2), we identified 15 as serovar L1, 18 as serovar L2
prototype, and 18 as the L2b variant. We sequenced the
complete ompA gene of 5 of these 18 L2b variants that
originated in San Francisco; all were identical to the
recently described L2b variant circulating in Amsterdam.
Four nucleotide changes were found when compared to
reference serovars L2, L2a, and the variant L2′, including
1 change that encoded the previously undescribed change
at amino acid 162, AAT→AGT (5).
Conclusions
The L2b LGV variant identified as the cause of all the
LGV proctitis in the recent outbreak among MSM in
Amsterdam appears to have been circulating in
Amsterdam in 2000. Moreover, we showed that this L2b
variant was present in the 1980s in San Francisco with
exactly the same mutations in the complete ompA gene.
However, since we only sequenced the ompA gene, and
although the sequence was identical in old and new L2b
strains, we cannot exclude the possibility that it could
involve different strains of C. trachomatis that differ in
other parts of the genome, although this is unlikely.
Since LGV causes potentially severe infections with
possibly irreversible sequelae if adequate treatment is not
begun promptly, early and accurate diagnosis is essential.
Sequence-based nucleic-acid tests that can discriminate
between LGV serovars and less invasive C. trachomatis
species can help detect cases and prevent further transmis-
sion of LGV.
In conclusion, our results suggest that we are dealing
with the same LGV variant >25 years later, and the current
LGV outbreak in industrialized countries has most likely
been a slowly evolving epidemic with an organism that has
gone unnoticed in the community for many years and is
now being detected by new technologies. The numbers
detected in 2005 in Amsterdam suggest that a considerable
reservoir exists, which emphasizes the need for ongoing
public health awareness.
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